ARDEN HILLS, Minn.--(BUSINESS WIRE)--IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced financial results for its first quarter ended March 31, 2016.
Highlights:
- Net sales of $18.3 million increased 10 percent over the prior-year period;
- The company’s value hearing health initiatives delivered both year-over-year and sequential growth;
- Gross margins of 28.0 percent improved from 26.1 percent in the first quarter of 2015; and,
- The company amended its credit facilities with The PrivateBank, creating a lending structure with broader financial flexibility.
First-Quarter Financial Results
For the 2016 first quarter, the company reported net sales of $18.3 million, up from $16.6 million in the prior-year period. Gross profit margins grew to 28.0 percent from 26.1 percent in the 2015 first quarter. The gains stemmed primarily from higher overall sales volume. IntriCon posted net income attributable to IntriCon shareholders of $15,000, or $0.00 per diluted share, compared to $284,000, or $0.05 per diluted share, for the 2015 first quarter.
“We are pleased to report year-over-year growth from a net sales and gross margin standpoint. We consciously increased our investment in the first quarter to accelerate expansion in value hearing health, which resulted in a slight decline in net income attributable to IntriCon shareholders,” said Mark S. Gorder, president and chief executive officer. “Our recent value hearing health efforts are beginning to gain traction and we delivered first-quarter net sales gains both year over year and sequentially. We intend to continue focusing our resources on building the infrastructure required to secure high-potential growth opportunities in the value hearing health market.”
Business Update
First-quarter hearing health sales grew 16 percent over the prior-year period. During the quarter, IntriCon experienced gains in value hearing aids, personal sound amplifier products (PSAP) and assisted listening devices. These were partially offset by anticipated decreases in conventional channel sales.
As previously noted, the conventional channel has experienced a trend of continuing market consolidation. As a result, six large manufacturers now control approximately 98 percent of the global market. However, market penetration has stagnated as end-consumer prices have risen dramatically. This has spurred the development of value hearing aids, PSAPs and assisted listening devices.
Moreover, on April 21, 2016, the U.S. Food and Drug Administration (FDA) hosted a public workshop to gather stakeholder and public input on draft guidance related to the agency's premarket requirements for hearing aids and PSAPs. The FDA’s intent is to consider ways in which regulation can support further device penetration into the hearing market.
“As a company, we are aligned with the FDA's efforts to overcome barriers to device access and spur development and innovation in cost-effective technology,” said Gorder. “We believe these factors create the need for the outcomes-based hearing health delivery model we’ve advocated. Our value hearing health strategy focuses on this need as we continue to build the infrastructure to secure other notable partners who can help drive the company's outcomes-based, hearing health delivery model.”
The company’s integration plan for PC Werth is proceeding on schedule. During the quarter, IntriCon delivered initial devices to the National Health Service and is eagerly awaiting customer feedback. In mid-April, earVenture, the company’s joint venture with the Academy of Doctors of Audiology (ADA), presented at AudiologyNOW!, the annual convention of the American Academy of Audiology. This is part of IntriCon’s comprehensive marketing and sales plan to convert the 400-plus ADA members who have registered to join the earVenture program, into consistent customers, as well as solicit non-registered ADA members to join.
On the medical front, sales in IntriCon’s medical business increased 12 percent in the 2016 first quarter compared to the prior-year first quarter, primarily driven by the company’s largest customer, Medtronic. The gains stemmed from MiniLink REAL-Time Transmitter and related accessories sales, which are incorporated in Medtronic's MiniMed 530G insulin pump and continuous glucose monitoring system. IntriCon anticipates Medtronic revenue gains throughout 2016.
First quarter 2016 professional audio communication sales were down 16 percent from the prior-year period. IntriCon will continue to leverage its core technologies in professional audio communication to support existing customers, as well as seek related hearing health and medical product opportunities.
On April 15, 2016, IntriCon amended its credit facilities with The PrivateBank. The amendment includes, among other things: an increase in IntriCon’s term loan to $6.0 million from $4.0 million; an increase in the revolving credit facility capacity to $9.0 million from $8.0 million; an increase in the inventory cap on the borrowing base from $3.5 million to $4.0 million; and, revisions to the leverage ratio financial covenants effective March 31, 2016.
Said Gorder, “The higher borrowing capacity of our amended credit facilities is an important step in advancing our future plans. As we look ahead, we are evaluating several options to enhance our infrastructure and secure channel partners in value hearing health. Further, continued core technology investments—including development of ultra-low-power wireless technology aimed to increase efficiencies and access through innovative value hearing health distribution channels and medical biotelemetry markets—are essential to our long-term success.”
Looking Ahead
Concluded Gorder, “I am encouraged with the
strong revenue and gross margins posted during the quarter and further
progress made in developing our value hearing health infrastructure and
advancing our technology portfolio. We are committed to accelerating
targeted investment that best position the company for long-term success
in the value hearing health and medical biotelemetry markets.
Financially, we anticipate second quarter net sales consistent with 2016
first-quarter levels and double-digit gains for the full year.”
Conference Call Today
As previously announced, the company
will hold an investment community conference call today, Tuesday, April
26, 2016, beginning at 4 p.m. CT. Mark Gorder, president and chief
executive officer, and Scott Longval, chief financial officer, will
review fourth-quarter performance and discuss the company’s strategies.
To join the conference call, dial: 1-800-344-6698 and provide the
conference ID number 7654838 to the operator.
A replay of the conference call will be available three hours after the call ends through 7:00 p.m. CT on Tuesday, May 10, 2016. To access the replay, please visit https://jsp.premiereglobal.com/webrsvp and enter passcode 7654838.
About IntriCon Corporation
Headquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops and manufactures miniature
and micro-miniature body-worn devices. These advanced products help
medical, healthcare and professional communications companies meet the
rising demand for smaller, more intelligent and better connected
devices. IntriCon has facilities in the United States, Asia, United
Kingdom and Europe. The company’s common stock trades under the symbol
“IIN” on the NASDAQ Global Market. For more information about IntriCon,
visit www.intricon.com.
Forward-Looking Statements
Statements made in this release
and in IntriCon's other public filings and releases that are not
historical facts or that include forward-looking terminology are
"forward-looking statements" within the meaning of the Securities
Exchange Act of 1934, as amended. These forward-looking statements may
be affected by known and unknown risks, uncertainties and other factors
that are beyond IntriCon's control, and may cause IntriCon's actual
results, performance or achievements to differ materially from the
results, performance and achievements expressed or implied in the
forward-looking statements. These risks, uncertainties and other factors
are detailed from time to time in the company's filings with the
Securities and Exchange Commission, including the Annual Report on Form
10-K for the year ended December 31, 2015. The company disclaims any
intent or obligation to publicly update or revise any forward-looking
statements, regardless of whether new information becomes available,
future developments occur or otherwise.
| INTRICON CORPORATION | ||||||||||
| Consolidated Condensed Statements of Operations | ||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||
| Three Months Ended | ||||||||||
| March 31, | March 31, | |||||||||
| 2016 | 2015 | |||||||||
| (Unaudited) | (Unaudited) | |||||||||
| Sales, net | $ | 18,258 | $ | 16,602 | ||||||
| Cost of sales | 13,144 | 12,274 | ||||||||
| Gross profit | 5,114 | 4,328 | ||||||||
| Operating expenses: | ||||||||||
| Sales and marketing | 1,196 | 987 | ||||||||
| General and administrative | 2,291 | 1,709 | ||||||||
| Research and development | 1,416 | 1,226 | ||||||||
| Total operating expenses | 4,903 | 3,922 | ||||||||
| Operating income | 211 | 406 | ||||||||
| Interest expense | (126 | ) | (103 | ) | ||||||
| Other income (expense) | (70 | ) | 136 | |||||||
| Income from continuing operations before income taxes | 15 | 439 | ||||||||
| Income tax (benefit) expense | 34 | 155 | ||||||||
| Net Income (Loss) | (19 | ) | 284 | |||||||
| Less: Loss allocated to non-controlling interest | (34 | ) | - | |||||||
| Net Income attributable to IntriCon shareholders | $ | 15 | $ | 284 | ||||||
| Net income per share attributable to IntriCon shareholders: | ||||||||||
| Basic | $ | 0.00 | $ | 0.05 | ||||||
| Diluted | $ | 0.00 | $ | 0.05 | ||||||
| Average shares outstanding: | ||||||||||
| Basic | 5,981 | 5,849 | ||||||||
| Diluted | 6,228 | 6,227 | ||||||||
| INTRICON CORPORATION | ||||||||||
| Consolidated Condensed Balance Sheets | ||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||
| March 31, | December 31, | |||||||||
|
2016 |
2015 |
|||||||||
| Current assets: | ||||||||||
| Cash | $ | 553 | $ | 369 | ||||||
| Restricted cash | 640 | 610 | ||||||||
| Accounts receivable, less allowance for doubtful accounts of $136 at March 31, 2016 and $135 at December 31, 2015 | 8,924 | 8,578 | ||||||||
| Inventories | 14,556 | 14,472 | ||||||||
| Other current assets | 932 | 860 | ||||||||
| Total current assets | 25,605 | 24,889 | ||||||||
| Machinery and equipment | 39,273 | 38,653 | ||||||||
| Less: Accumulated depreciation | 32,367 | 31,911 | ||||||||
| Net machinery and equipment | 6,906 | 6,742 | ||||||||
| Goodwill | 9,551 | 9,551 | ||||||||
| Investment in partnerships | 188 | 224 | ||||||||
| Other assets, net | 1,052 | 480 | ||||||||
| Total assets | $ | 43,302 | $ | 41,886 | ||||||
| Current liabilities: | ||||||||||
| Current maturities of long-term debt | $ | 1,941 | $ | 1,908 | ||||||
| Accounts payable | 8,275 | 7,785 | ||||||||
| Accrued salaries, wages and commissions | 1,918 | 2,559 | ||||||||
| Deferred gain | 28 | 55 | ||||||||
| Other accrued liabilities | 965 | 1,279 | ||||||||
| Total current liabilities | 13,127 | 13,586 | ||||||||
| Long-term debt, less current maturities | 9,603 | 7,929 | ||||||||
| Other postretirement benefit obligations | 530 | 542 | ||||||||
| Accrued pension liabilities | 824 | 812 | ||||||||
| Other long-term liabilities | 137 | 120 | ||||||||
| Total liabilities | 24,221 | 22,989 | ||||||||
| Commitments and contingencies | ||||||||||
| Shareholders’ equity: | ||||||||||
| Common stock, $1.00 par value per share; 20,000 shares authorized; 5,986 and 5,981 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively | 5,986 | 5,981 | ||||||||
| Additional paid-in capital | 17,922 | 17,721 | ||||||||
| Accumulated deficit | (4,031 | ) | (4,046 | ) | ||||||
| Accumulated other comprehensive loss | (723 | ) | (721 | ) | ||||||
| Total shareholders' equity | 19,154 | 18,935 | ||||||||
| Non-controlling interest | (73 | ) | (38 | ) | ||||||
| Total equity | 19,081 | 18,897 | ||||||||
| Total liabilities and equity | $ | 43,302 | $ | 41,886 | ||||||